吉西他滨联合大黄素胶囊治疗胰腺癌临床效果观察  

Efficacy of Gemcitabine Combined With Emodin Capsule for Patients with Pancreatic Cancer

作　　者：王福生 蒋国祯 吴周环[2] 

机构地区：[1]金华医学院附属医院肝胆外科,浙江金华321000 [2]九江学院医学院,江西九江332000

出　　处：《九江学院学报（自然科学版）》2011年第4期47-49,54,共4页Journal of Jiujiang University：Natural Science Edition

摘　　要：目的:观察吉西他滨联合大黄素胶囊治疗胰腺癌的临床疗效。方法:对44例胰腺癌患者分成治疗组和对照组,22例治疗组采用吉西他滨化疗联合大黄素胶囊综合治疗;22例对照组只用吉西他滨化疗。比较两组临床疗效。结果:治疗组治疗后3月VEGF、CAl9-9下降水平以及6个月临床收益反应优于对照组,血液和胃肠道化疗不良反应少于对照组(均p<0.05),两组客观有效率和中位生存时间差异无统计意义,(p>0.05)。结论:吉西他滨为主,辅以大黄素胶囊综合化疗能改善肿瘤生活质量,降低患者的肿瘤负荷。Objective ： to evaluate the clinical efficacy of gemcitabine combined with emodin capsule for the pancreatic cancer. Method： 44 pancreatic cancer patients were divided into the treaded group with 22 cases received gemcitabine chemotherapy combining with emodin capsule and the control group with 22 cases only received gemcitabine chemotherapy. were compared. Results： after the 3th months treatment, The clinical effectiveness among two groups the decreased levels of VEGF and CA19 - 9 in the treaded group were significantly higher than those in the control group （p 〈 0. 05）, the incidence of blood and gastrointestinal side - effects in the treaded group were signifi- cantly lower than those in the control group （p 〈0. 05）. The difference of clinical benefit response rates was no significant between the two groups on the 3rd month , but that was significant higher in the treaded group after the 6th month . The difference in the rates of objective tumor response and the median survival were no significant between the two groups （p 〉 0. 05 ）. Conclusion： Gemcitabine - based chemotherapy supplemented by emodin capsules can improve quality of life of pancreatic cancer patients and reduce the patient＇s tumor burden.

关 键 词：胰腺癌 吉西他滨 大黄素胶囊 临床疗效 

分 类 号：R735.9[医药卫生—肿瘤]